EGFR and non-small cell lung carcinoma: In several studies, patients with EGFR‐mutant LA‐NSCLC were found to have shorter progression‐free survival (PFS) than those without EGFR mutations,5, 6, 7 whereas another study showed that patients with LA‐NSCLC with EGFR‐sensitizing mutations had a trend toward improvement in the overall response rate (ORR) compared with patients without EGFR mutations, with no significant differences in relapse‐free survival (RFS) and overall survival (OS).12